AN2 Therapeutics, Inc.ANTXNASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank74
3Y CAGR-2.9%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
-2.9%/yr
Quarterly compound
Percentile
P74
Within normal range
vs 3Y Ago
0.9x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 17.87% |
| Q3 2025 | 16.11% |
| Q2 2025 | 28.47% |
| Q1 2025 | -101.48% |
| Q4 2024 | 56.08% |
| Q3 2024 | 16.53% |
| Q2 2024 | 18.24% |
| Q1 2024 | -3.08% |
| Q4 2023 | -44.64% |
| Q3 2023 | 7.99% |
| Q2 2023 | -10.59% |
| Q1 2023 | -51.82% |
| Q4 2022 | 19.49% |
| Q3 2022 | 1.13% |
| Q2 2022 | -42.32% |
| Q1 2022 | 25.03% |
| Q4 2021 | -91.71% |
| Q3 2021 | 10.77% |
| Q2 2021 | -240.70% |
| Q1 2021 | 0.00% |